Karyopharm Therapeutics (KPTI) – Corporate News
-
Karyopharm Therapeutics (KPTI) Announces Preliminary Unaudited 2023 Revenue and 2024 Objectives
-
Karyopharm Therapeutics (KPTI) Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Novel CELMoD™ Agent CC- 92480 Mezigdomide in Combination with Selinexor
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to KPTI Stock Lookup